Imaging of CB1 Receptors Using (11C)SD5024

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1

Total Enrollment

8 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-06-22

Study Completion Date

2013-12-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background:

\- The cannabinoid type 1 (CB1) receptor is a protein found on some brain cells. It may play a role in obesity or some psychiatric disorders such as schizophrenia. Imaging studies like positron emission tomography (PET) can show where CB1 receptors are located. A new radioactive chemical, 11C-SD5024, may be able to show these receptors more clearly than previous radioactive chemicals. Better images of CB1 receptors in the brain may help improve our understanding of obesity and psychiatric disorders. This information may lead to better treatments.

Objectives:

\- To test how well a new radioactive chemical, 11C-SD5024, is taken up by the brain during imaging studies.

Eligibility:

\- Healthy volunteers between 18 and 50 years of age who are able to have positron emission tomography scans.

Design:

* All participants will be screened with a physical exam, medical history, and blood tests.
* Participants will be in one of three groups for the study. Each group will receive 11C-SD5024 and have a different set of imaging studies.
* Group 1 will have a magnetic resonance imaging (MRI) scan and PET scan of the brain. They will also have blood and urine tests.
* Group 2 will have a whole-body PET scan, as well as blood and urine tests.
* Group 3 will have an MRI scan of the brain, followed by two PET scans of the brain. They will also have blood and urine tests. The two PET scans can happen on the same day or on two different days.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Imaging Cannabinoid CB1 Receptors in Schizophrenia

NCT01063335

Schizophrenia

TERMINATED

Imaging of Brain Receptors in Healthy Volunteers and in Patients With Schizophrenia

NCT00061789

Schizophrenia

COMPLETED PHASE2

Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography

NCT00942981

Schizoaffective Disorder Schizophrenia

COMPLETED

KetoBrain: Brain Energy Metabolism in Schizophrenia

NCT07309172

Schizophrenia Disorder

RECRUITING

M1 Schizophrenia PET Study

NCT05105542

Schizophrenia Schizoaffective Disorder Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The cannabinoid type 1 (CB(1)) receptor is one of the most abundant G protein-coupled receptors in the brain (Matsuda et al 1990). It is found on glutamatergic, dopaminergic, and gamma aminobutyric acid (GABA)-ergic synaptic terminals and mediates the effects of endocannabinoids (ECs), which suppresses the release of neurotransmitters. The CB(1) receptor is a target for drug therapy, including the use of a CB(1) receptor antagonist as an appetite suppressant. Our laboratory recently developed a promising positron emission tomography (PET) ligand for the CB(1) receptor: \[(11)C\]SD5024 (Donohue et al 2008a).

Previous studies from our laboratory used two PET ligands to image CB(1) receptors (11)C-MePPEP and (18)F-FMPEP-d(2) (Yasuno et al 2008; Donohue et al 2008b) and found that the latter provides more accurate and precise measurement. We also found that clearance of (11)C-MePPEP from brain was too slow for (11)C-labeling (Terry et al 2010). Although we are currently using \[(18)F\]FMPEP-d(2) , the major disadvantage of the current radioligand is that it washes out slowly from the brain, and accurate quantitation requires relatively fast washout. If \[(11)C\]SD5024 is amenable to quantitation in human subjects, then it may prove to be a useful ligand for studying potential pathophysiological changes of this receptor.

The purpose of this protocol is (1) to perform brain imaging using \[(11)C\]SD5024 in healthy volunteers to characterize brain uptake and distribution; (2) to perform whole body PET studies in healthy volunteers in order to estimate radiation absorbed doses for \[(11)C\]SD5024; and (3) to perform brain test-retest studies in healthy volunteers to further examine how precise measurements of receptor binding are, and to determine optimal parameters for future experiments using \[(11)C\]SD5024.

Successful development of a PET radioligand to image CB1 receptors has the potential to significantly impact our understanding and clinical management of neuropsychiatric (eg, schizophrenia) (Eggan et al 2008) and metabolic (eg, obesity) (Gazzerro et al 2007) disorders. Future experiments would include studies of relevant neuropsychiatric disorders.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Brain Scan-PET

Intervention Type PROCEDURE

Brain Scan-MRI

Intervention Type PROCEDURE

Arterial Line

Intervention Type PROCEDURE

Venous Line

Intervention Type PROCEDURE

Blood Sampling

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Healthy control subjects aged 18 50 whose medical history, physical exam, electrocardiogram (ECG), and laboratory test results are within normal limits within one year of the PET scan will be eligible to participate.

Exclusion Criteria

Any recent or past history of psychiatric illness or severe systemic disease based on history and physical exam.

Serious medical illness likely to modify brain anatomy and/or physiology (head trauma, past brain surgery, neurological disorders such as epilepsy, Parkinson disease, and psychiatric disorders such as schizophrenia and depression)

Any current substance or alcohol abuse, with the exception of nicotine.

Positive urine toxicology screen

Radiation exposure from participation in other research protocols in the last year such that the additional radiation exposure from this protocol would exceed annual limits.

Pregnant or breastfeeding.

Claustrophobia (applies to Parts 1 and 3 only).

Metallic (ferromagnetic) implants, including pacemakers or other implanted electrical devices, brain stimulators, some types of dental implants, aneurysm clips (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and cochlear implants), permanent eyeliner, implanted delivery pump, shrapnel fragments, and possible small metal fragments in the eye (applies to Parts 1 and 3 only).

Unable to lie flat on back for up to 2.5 hours.

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes